Treatment of indolent systemic mastocytosis with sarilumab is not supported in a randomized trial
Background: Indolent systemic mastocytosis is a clonal mast cell disease that results in an increase in mast cells in the skin, bone marrow, and other organ systems. IL-6 has been shown to promote mast cell maturation, proliferation, and reactivity in vitro. Serum levels of IL-6 correlate with sever...
Saved in:
| Main Authors: | Hirsh D. Komarow, MD, Jing Wang, MS, Robin Eisch, RN, Linda Scott, CRNP, Erica H. Brittain, PhD, Dean D. Metcalfe, MD, MS |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | Journal of Allergy and Clinical Immunology: Global |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772829325000992 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Difficulties of primary diagnosis in patients with suspected systemic mastocytosis
by: Z. K. Abdulkhalikova, et al.
Published: (2024-09-01) -
Mast cell activation syndrome: The overdiagnosis problems
by: N. V. Mikryukova, et al.
Published: (2025-06-01) -
A cross‐sectional study on quality of life in adult indolent systemic mastocytosis and its association with cutaneous involvement
by: Eugenio Isoletta, et al.
Published: (2025-03-01) -
Urticaria pigmentosa: A case report
by: Mohammad Abid Keen
Published: (2016-01-01) -
Urticaria pigmentosa: A case report
by: Mohammad Abid Keen
Published: (2016-01-01)